Terms: = Thyroid cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
40 results:
1. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
2. TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary thyroid Carcinoma in a Colombian Cohort.
Cruz-Romero SD; González S; Juez JY; Becerra DS; Baldión AM; Hakim JA; González-Devia D; Perdomo S; Rodríguez-Urrego PA
Adv Ther; 2024 Feb; 41(2):792-805. PubMed ID: 38170436
[TBL] [Abstract] [Full Text] [Related]
3. cdk4 phosphorylation status and rational use for combining cdk4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract] [Full Text] [Related]
4. Comparative efficacy and safety of different combinations of three cdk4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.
Liu Y; Wu J; Ji Z; Chen L; Zou J; Zheng J; Lin W; Cai J; Chen Y; Zheng D; Chen Y; Li Z
BMC Cancer; 2023 Aug; 23(1):816. PubMed ID: 37653504
[TBL] [Abstract] [Full Text] [Related]
5. p18INK4C and BRCA1 inhibit follicular cell proliferation and dedifferentiation in thyroid cancer.
Bai F; Liu X; Zhang X; Mao Z; Wen H; Ma J; Pei XH
Cell Cycle; 2023 Jul; 22(13):1637-1653. PubMed ID: 37345432
[TBL] [Abstract] [Full Text] [Related]
6. Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of cdk4/6 Inhibition.
Hu Q; Huang T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240281
[TBL] [Abstract] [Full Text] [Related]
7. Differentiated thyroid cancer in Adolescents: Single Center Experience and Considerations for Surgical Management and Radioiodine treatment.
Chiapponi C; Hartmann MJM; Decarolis B; Simon T; Bruns CJ; Faust M; Schultheis AM; Schmidt M; Alakus H
J Clin Res Pediatr Endocrinol; 2023 Aug; 15(3):257-263. PubMed ID: 36987773
[TBL] [Abstract] [Full Text] [Related]
8. The effects of Abemaciclib on cell cycle and apoptosis regulation in anaplastic thyroid cancer cells.
Abutorabi ES; Poursheikhani A; Kashani B; Shamsaiegahkani S; Haghpanah V; Bashash D; Mousavi SA; Momeny M; Ghaffari SH
Mol Biol Rep; 2023 May; 50(5):4073-4082. PubMed ID: 36877344
[TBL] [Abstract] [Full Text] [Related]
9. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
Yang J; Zhao B; Ling X; Li D; Zhao J; Lv Y; Wang G; Liu X; Li N; Yang J
BMC Cancer; 2023 Jan; 23(1):103. PubMed ID: 36717797
[TBL] [Abstract] [Full Text] [Related]
10. Role of synaptotagmin 13 (SYT13) in promoting breast cancer and signaling pathways.
Zhang YD; Zhong R; Liu JQ; Sun ZX; Wang T; Liu JT
Clin Transl Oncol; 2023 Jun; 25(6):1629-1640. PubMed ID: 36630025
[TBL] [Abstract] [Full Text] [Related]
11. Disulfiram/Copper Suppresses cancer Stem Cell Activity in Differentiated thyroid cancer Cells by Inhibiting BMI1 Expression.
Ni YL; Chien PJ; Hsieh HC; Shen HT; Lee HT; Chen SM; Chang WW
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362068
[TBL] [Abstract] [Full Text] [Related]
12. cdk4/6 inhibitor resistance mechanisms and treatment strategies (Review).
Huang J; Zheng L; Sun Z; Li J
Int J Mol Med; 2022 Oct; 50(4):. PubMed ID: 36043521
[TBL] [Abstract] [Full Text] [Related]
13. Overexpressed Cyclin D1 and cdk4 proteins are responsible for the resistance to cdk4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.
Cai Z; Wang J; Li Y; Shi Q; Jin L; Li S; Zhu M; Wang Q; Wong LL; Yang W; Lai H; Gong C; Yao Y; Liu Y; Zhang J; Yao H; Liu Q
Sci China Life Sci; 2023 Jan; 66(1):94-109. PubMed ID: 35982377
[TBL] [Abstract] [Full Text] [Related]
14. Effects of Ruxolitinib and Calcitriol Combination treatment on Various Molecular Subtypes of Breast cancer.
Schneider J; Jeon YW; Suh YJ; Lim ST
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269680
[TBL] [Abstract] [Full Text] [Related]
15. The anti-cancer role of microRNA-143 in papillary thyroid carcinoma by targeting high mobility group AT-hook 2.
Ding C; Shi T; Wu G; Man J; Han H; Cui Y
Bioengineered; 2022 Mar; 13(3):6629-6640. PubMed ID: 35213273
[TBL] [Abstract] [Full Text] [Related]
16. Surveillance, Epidemiology, and End Results Database update for pediatric thyroid carcinomas incidence and survival trends 2000-2016.
Tawde A; Jeyakumar A
Int J Pediatr Otorhinolaryngol; 2022 Feb; 153():111038. PubMed ID: 34998202
[TBL] [Abstract] [Full Text] [Related]
17. Over expression of cdk4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.
Hou TC; Wu PS; Huang WY; Yang YT; Tan KT; Liu SH; Chen YJ; Chen SJ; Su YW
Medicine (Baltimore); 2020 Mar; 99(12):e19577. PubMed ID: 32195970
[TBL] [Abstract] [Full Text] [Related]
18. Salutary Response to Targeted Therapy in Anaplastic thyroid cancer.
Fazeli S; Paal E; Maxwell JH; Burman KD; Nylen ES; Khosla SG
J Investig Med High Impact Case Rep; 2019; 7():2324709619890942. PubMed ID: 31766881
[No Abstract] [Full Text] [Related]
19. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma.
Alqahtani T; Kumarasamy VM; Huczyński A; Sun D
Int J Oncol; 2020 Jan; 56(1):348-358. PubMed ID: 31746350
[TBL] [Abstract] [Full Text] [Related]
20. MiR-128-3p suppresses breast cancer cellular progression via targeting LIMK1.
Zhao J; Li D; Fang L
Biomed Pharmacother; 2019 Jul; 115():108947. PubMed ID: 31078043
[TBL] [Abstract] [Full Text] [Related]
[Next]
